Bio-Rad Laboratories COO Jonathan DiVincenzo Receives RSU Grant and Vests Shares
BIO-RAD LABORATORIES, INC.
Subscribe to track BIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filing Alert: BIO-RAD LABORATORIES, INC. ($BIO)
Insider: DiVincenzo Jonathan P. (President & COO) Filing Date: 2026-09-09 Summary: ā¢ Granted 6,326 Restricted Stock Units (RSUs) on 2026-09-04. ā¢ Acquired 1,712 Class A shares via RSU vesting on 2026-09-05. ā¢ Disposed of 668 shares at $386.11 ($257,921.48) to cover tax withholding liabilities. ā¢ Direct Class A holdings post-transaction: 1,963 shares.
Significance: Low (Routine RSU grant, vesting, and tax withholding).
Comprehensive Analysis
Bio-Rad Laboratories, Inc. (BIO) Form 4 Analysis
Executive Summary
On September 9, 2026, Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, Inc., filed a Form 4 disclosing routine equity compensation transactions and tax withholdings:
- Equity Award Grant (2026-09-04): Received an award of 6,326 Restricted Stock Units (RSUs) vesting over four years (25% on year one, quarterly thereafter).
- RSU Vesting (2026-09-05): 1,712 RSUs vested and converted into Class A Common Stock on a 1-for-1 basis.
- Tax Withholding (2026-09-05): 668 shares were withheld at a price of $386.11 per share (total value of $257,921.48) to satisfy statutory tax obligations.
Post-Transaction Holdings
- Direct Common Stock Holdings: 1,963 shares
- Derivative Holdings (RSUs remaining from grant): 5,138 RSUs (from the earlier tranche) plus 6,326 RSUs (new grant)
Market Impact & Interpretation
This filing reflects standard executive equity compensation activity, including an annual/periodic grant, scheduled vesting, and tax withholding. It does not reflect discretionary open-market buying or selling and carries low trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.